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Previous reports from our laboratory have demonstrated the stimulation of specific 
suppressor T cells in genetic nonresponder mice after immunization with the terpolymer 
of L-glutamic acid, L-alanine, and L-tyrosine (GAT)  (1, 2) and with the copolymer of L- 
glutamic acid and L-tyrosine (GT) (3-5). These findings raise two important questions: (a) 
do the specific  suppressor T  cells  inhibit an antibody response which would otherwise 
develop in nonresponder mice; and, (b) can specific helper T-cell activity be detected in 
these animals.  Responsiveness appears to be completely dominant over suppression in 
(responder × suppressor)F1  hybrids, therefore, we have been unable to detect suppressor 
cells in these hybrids after conventional immunization with GAT (2). However, using 
special conditions of antigen administration, GAT helper activity could be demonstrated 
in nonresponder DBA/1 ("suppressor") mice. Thus, GAT-specific  helper activity was not 
detected in these nonresponder animals after immunization with GAT irrespective of the 
adjuvant used, but could be stimulated by macrophage-bound GAT or by GAT cemplexed 
with methylated bovine serum albumin GAT-MBSA (6). 
In the current report we have taken advantage of the fact that suppressor T- 
cell activity is more sensitive to cyclophosphamide  treatment than T-cell helper 
activity (7) to demonstrate the presence of GT-specific helper activity in "nonre- 
spondee' BALB/c  mice.  We  describe:  (a)  the  dose  of cyclophosphamide and 
conditions of treatment which inhibits  the  well-documented stimulation of 
specific suppressor T cells in BALB/c mice injected with GT previous to immuni- 
zation with GT-MBSA, and (b) the ability of cyclophosphamide to permit the 
development of primary PFC responses to GT in these "nonresponde~' mice. 
These cyclophosphamide-induced  responses are not characterized by the high 
levels of antibody detected in genetic responder animals. 
Materials and Methods 
Mice.  The mice were purchased from The Health  Research Laboratories,  Buffalo, N. Y., or 
were bred in our animal facilities. 
Antigens.  The antigens and hemolytic plaque assay used in these experiments are the same as 
those described in the companion paper (5). 
Immunization and Treatment with Cyclophosphamide.  Cyclophosphamide (Cytoxan) was pur- 
chased from Mead-Johnson Laboratories, Evansville, Ind. The drug was administered intraperito- 
neally in the dose of 200 mg/kg. To investigate the effect of the drug on the suppressive activity of 
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GT, BALB/c mice were injected  intraperitoneally  with cyclophosphamide followed 2 days later 
with 100  ~g GT in  a mixture  of  magnesium and  aluminum hydroxides (Maalox, William H. Rorer, 
Inc., Fort Washington,  Pa.) or with Maalox alone. 10 days later,  the mice were immunized 
intraperitoneally with 10 pg of GT as GT-MBSA  emulsified in an equal volume of complete 
Freund's adjuvant (CFA) (Difco  Laboratories,  Detroit,  Mich.).  To  study  the  effect  ofcyclophospha- 
mide on responsiveness to GT, other groups of  BALB/c mice were injected  with the drug or with 
physiological  saline  intraporitoneally  (Group V and VI of  Table I) and 12 days later  immunized 
with 100 ~g GT in CFA. 
GT-Specific Suppressor Extract and Control Maalox Extract.  GT-specific  suppressor extract 
was prepared by ultransonification and ultracentrifugation of thymocytes and spleen cells from 
BALB/c mice immunized 3 days previously with 100 ~g GT in Maalox, as described previously (8, 
9).  As control,  an  extract referred to as  Maalox extract was prepared  similarly from cells of 
animals injected with Maalox alone. The details of the preparations and the properties of the GT- 
specific suppressor factor on the primary PFC response of BALB/c to GT-MBSA will be described 
separately. I The GT-spocific suppressor extract behaved like the GAT-specific suppressor factor(s) 
previously described by this laboratory (9). 
Antigen-Binding Assay.  The humoral response to GT was measured by antigen-binding assay 
employing the homologous GT copolymer.  GT was iodinated by the chloramine-T method with 
carrier-free '2'~I (New England Nuclear, Boston,  Mass.)  and separated from inorganic iodide by 
passage over 0.5 x 25-cm columns of Sephadex G-25F (Pharmacia Fine Chemicals, Piscataway, N. 
J.).  Serum samples diluted 1:5 with phosphate-buffered saline were assayed by modified Farr 
assay which has been described previously (10). 
Results and Discussion 
As shown in Table I, 12 days were allowed to elapse between treatment with 
cyclophosphamide and immunization with GT-MBSA to permit recovery of B- 
cell function. The comparable responses of Group I and III indicate that cyclo- 
phosphamide in the dose and time used did not affect the primary response to 
GT-MBSA when assayed 7 days later. The suppressive effects normally induced 
by GT preimmunization, however, were completely abolished by this treatment 
(compare Groups  I  and II  and II  and  IV,  respectively). This  effect may be 
interpreted to reflect the inhibitory activity of the drug on the stimulation of GT- 
specific suppressor T cells. 
But the most interesting result is the development of GT-specific primary IgG 
responses in animals treated with cyclophosphamide 12 days earlier (Groups V 
and VI). The response to GT immunization after this treatment were unequivo- 
cal and did not differ significantly from the responses of control mice to GT- 
MBSA (Groups I and VI); however, no specific IgM responses have been detected 
in animals treated with cyclophosphamide. 
The antigen-binding values of the sera from animals treated with cyclophos- 
phamide presented in Table II show that the responses to GT in these animals 
are  seen early after primary immunization and  do  not progress  in  spite  of 
secondary challenge. On the whole, these responses are considerably weaker 
than are observed in genetic responder (C3H x GT Swiss responder)F, mice not 
treated with cyclophosphamide. The reason for the limited anti-GT responses 
observed may be the weak responsiveness of the BALB/c animals or the recovery 
of suppressor cell activity after the cyclophosphamide treatment or both.  Re- 
sponsiveness to GT is only observed in some Swiss mice (3). The data in Table II 
on the responses of (C3H  x  GT Swiss responder)F, mice, which segregate into 
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TABLE  I 
Effect of Cyclophosphamide  on GT-Specific Suppression  in BALB/c Mice 
279 
Group  No. animals  Day 0  Day 2  Day 12  IgG-Specific PFC/  P value 
per group  spleen 
Arith. mean ± SE 
I  9  Saline  Maalox  GT-MBSA*  9,800 ±  1,256 
<0.0001 
II  ii  Saline  GT*  GT-MBSA  2,390 -+ 8~ 
III  12  Cyclophosphamide§  Maalox  GT-MBSA  12,864 ± 2,220  NS 
IV  12  Cyclophosphamide  GT  GT-MBSA  14,050 -+ 2,807 
V  10  Saline  -  G~[  605 ± 525  <0.0003 
VI  18  Cyclophosphamide  -  GT  6,705 _+ 1,071 
* 10/~g GT as GT-MBSA in CFA intraperitoneally. 
100/~g GT in Maalox intraperitoneally. 
§ 200 mg of cyclophosphamide/kg intraperitoneally. 
][ 100 ~g GT in CFA intraperitoneally. 
TABLE II 
Effect of Cyclophosphamide  on GT Antibody Responses in BALB/c Mice 
Strain 
Immunization schedule  GT binding -:_  SE (no.  of  mice) 
Day 0  Day 2  Day  11  Day 11  Day 23 
% 
BALB/c  -  GT*  GT  -1.9 -+ 2.3 (5)  1.5 ± 3.9 (5) 
BALB/c  Cyclophosphamide$  GT  GT  11.3 ±  I.I (15)  11.6 ~ 3.6 (9) 
(C3H x GT Swiss respenderlFL  -  GT  -  -  35.4 ± 6.5 (7) 
(C3H x GT Swiss responderlFt  -  GT  -  -  4.1 ± 2.7 (7) 
* GT 100 p.g in CFA. BALB/c Day 11 binding values were significantly different P  >  0.0001. 
Cyclophosphamide 200 mg/kg. 
TABLE  III 
Effect of Cyclophosphamide on Specific Suppression  by GT Extract in BALB/c Mice 
Group  No. animals  Day O  Day 9  Day 12  IgG-Specific PFC/  Suppres-  P  value 
per group  GT-MBSA$  spleen  sion 
Arith. mean  ± SE  % 
I  5  Cyclophos-  Maalox  -  6,775 ±  1,418 
phamide*  12  NS 
II  5  Cyclophos-  GT  -  5,970 ±  2,583 
phamide 
Ill  5  Saline  -  Maalox extract  6,540 *-. 842  91  <0.0001 
IV  5  Saline  GT extract  560 ± 290 
V  7  Cyclophas-  -  Maalox extract  5,300 ±  1,075 
phamide  62  <0.02 
VI  7  Cyclophos-  GT extract  2,021  -* 679 
phamide 
Same legends as Table I. 
* 200 mg of cyclophosphamide/kg intraperitoneally. 
$ On day 12 all mice were given the indicated extract plus 10 ~g GT as GT-MBSA in CFA, i.p. 
equal numbers of responders and nonresponders, demonstrate that the parental 
Swiss responder mice were heterozygous for the GT gene(s). 
The demonstration of the suppressor activity for the GT-MBSA responses of 
extracts prepared from thymus and spleen cells of GT-primed mice' raised the 
question whether treatment with cyclophosphamide inhibits the stimulation of 
suppressor activity or renders the cells of the immune spleen insensitive to the 
suppressive activity of the GT-specific "suppressor factor." This issue was ex- 
plored in the experiments in Table III. 
BALB/c mice were injected with 0.5 ml of 1/2 dilution of extracts prepared 
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GT in Maalox or Maalox alone 3 days previously. The extracts were injected 
intravenously on the day when the animals were immunized with GT-MBSA. 
The data show that cyclophosphamide treatment inhibits GT-specific suppres- 
sion normally caused by GT preimmunization but not by the injection of GT- 
specific suppressor extracts.  The suppressive activity observed in the normal 
animals treated with suppressor extract was greater than that seen in animals 
treated with cyclophosphamide. However, the difference between Groups IV and 
VI was not statistically significant. 
The results of these experiments imply that the helper and suppressor activity 
for distinct thymus-dependent antigens is under a delicate balance controlled by 
genes within the I region of the H-2 complex. The critical problem remaining to 
be resolved is the mechanism whereby specificity for the antigens is manifested 
by the processes controlled by individual Ir and Is genes, which have been shown 
to regulate immune responses to thymus-dependent antigens. 
Received for publication 1 April 1976. 
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